120 related articles for article (PubMed ID: 38464238)
1. KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation.
Budyagan K; Cannon AC; Chatoff A; Snyder NW; Kurimchak AM; Duncan JS; Chernoff J
Res Sq; 2024 Feb; ():. PubMed ID: 38464238
[TBL] [Abstract][Full Text] [Related]
2. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
Budagyan K; Chernoff J
Methods Mol Biol; 2021; 2262():323-334. PubMed ID: 33977487
[TBL] [Abstract][Full Text] [Related]
3. Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Thangaiyan R; Aljahdali IA; Lent-Moore KY; Liao J; Ling X; Li F
Am J Transl Res; 2021; 13(7):7458-7474. PubMed ID: 34377229
[TBL] [Abstract][Full Text] [Related]
4. A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.
Budagyan K; Cannon AC; Chernoff J
Methods Mol Biol; 2024; 2797():351-362. PubMed ID: 38570472
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
6. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
7. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
9. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
[TBL] [Abstract][Full Text] [Related]
10. Mutation-Specific and Common Phosphotyrosine Signatures of
Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
[No Abstract] [Full Text] [Related]
11. KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.
Modest DP; Camaj P; Heinemann V; Schwarz B; Jung A; Laubender RP; Gamba S; Haertl C; Stintzing S; Primo S; Bruns CJ
J Cancer Res Clin Oncol; 2013 Jun; 139(6):953-61. PubMed ID: 23455880
[TBL] [Abstract][Full Text] [Related]
12. Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations.
Hammond DE; Mageean CJ; Rusilowicz EV; Wickenden JA; Clague MJ; Prior IA
J Proteome Res; 2015 Mar; 14(3):1535-46. PubMed ID: 25599653
[TBL] [Abstract][Full Text] [Related]
13. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab.
Fiala O; Buchler T; Mohelnikova-Duchonova B; Melichar B; Matejka VM; Holubec L; Kulhankova J; Bortlicek Z; Bartouskova M; Liska V; Topolcan O; Sedivcova M; Finek J
Tumour Biol; 2016 May; 37(5):6823-30. PubMed ID: 26662311
[TBL] [Abstract][Full Text] [Related]
14. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
[TBL] [Abstract][Full Text] [Related]
15. Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.
Kawaguchi Y; Hinoi T; Saito Y; Adachi T; Miguchi M; Niitsu H; Sasada T; Shimomura M; Egi H; Oka S; Tanaka S; Chayama K; Sentani K; Oue N; Yasui W; Ohdan H
J Gastroenterol; 2016 May; 51(5):447-57. PubMed ID: 26361962
[TBL] [Abstract][Full Text] [Related]
16. Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells.
Hindul NL; Abbott LR; Adan SMD; Straatman KR; Fry AM; Hirota K; Tanaka K
J Biol Chem; 2024 May; 300(6):107409. PubMed ID: 38796063
[TBL] [Abstract][Full Text] [Related]
17. BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S; Maruyama K; Chen K; Takahashi Y; Hatakeyama K; Ohshima K; Shimoda Y; Sakai A; Kamada F; Nakatani S; Naruoka A; Ohnami S; Kusuhara M; Akiyama Y; Kagawa H; Shiomi A; Nagashima T; Urakami K; Yamaguchi K
Mol Cell Biochem; 2021 Sep; 476(9):3469-3482. PubMed ID: 33982211
[TBL] [Abstract][Full Text] [Related]
18. Not all mutations of
Li W; Liu Y; Cai S; Yang C; Lin Z; Zhou L; Liu L; Cheng X; Zeng W
Int J Clin Exp Pathol; 2019; 12(3):957-967. PubMed ID: 31933906
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.
Stolze B; Reinhart S; Bulllinger L; Fröhling S; Scholl C
Sci Rep; 2015 Feb; 5():8535. PubMed ID: 25705018
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and patterns of mutations in RAS/RAF/MEK/ERK/MAPK signaling pathway in colorectal cancer in North Africa.
Jafari M; Laraqui A; Baba W; Benmokhtar S; Zaitouni SE; Ali AA; Bounaim A; Moujahid M; Tanz R; Mahfoud T; Sbitti Y; Annaz HE; Abi R; Tagajdid MR; Kochri SE; Lahlou IA; Hsaini HE; Belayachi L; Benjouad A; Ichou M; En-Nya A; Ennibi K
BMC Cancer; 2022 Nov; 22(1):1142. PubMed ID: 36344948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
